Skip to main content

Table 1 Infant and maternal baseline characteristics among 737 HIV-exposed infants by infant HIV status at 12 months of life in Pune, India

From: High Rates of All-cause and Gastroenteritis-related Hospitalization Morbidity and Mortality among HIV-exposed Indian Infants

 

Total N

HIV- infected

N = 93

HIV-exposed, uninfected

N = 644

P-value‡

Infant Characteristics

   Female gender, n (%)

737

46 (49)

301 (47)

0.62

   Gestational age (weeks), median (IQR)

732

39 (38-40)

39 (38-40)

0.13

   APGAR at 5 minutes, median (IQR)

737

8 (8-9)

8 (8-9)

0.48

   Birth weight (grams), median (IQR)

732

2550 (2450-2950)

2650 (2400-3000)

0.29

   WHO-guided Cotrimoxazole use

737

61 (66)

247 (38)

<0.001

   Any breastfeeding (days), median (IQR)

718

171 (98-276)

101 (98-182)

0.03

<4 months, n (%)

398

42 (45)

356 (57)

 

4 - 6 months, n (%)

75

6 (6)

69 (11)

0.02

>6 months, n (%)

264

45 (48)

219 (34)

 

   Extended dose nevirapine, n (%)

737

41 (44)

326 (51)

0.24

   Infant HAART, n (%)†

737

15 (16)

n/a

n/a

Maternal Characteristics

   Age (years), median (IQR)

733

24 (21-26)

23 (21-25)

0.09

   Gravidity, median (IQR)

619

2 (1-3)

2 (1-3)

0.01

   Married, n (%)

733

90 (97)

624 (97)

>0.99

   Education

737

   

Primary (<6 years), n (%)

294

44 (48)

250 (39)

 

Secondary (6-10 years), n (%)

376

39 (42)

337 (52)

0.17

Tertiary (>10 years), n (%)

67

10 (12)

57 (9)

 

   Hindu religion, n (%)

733

76 (82)

493 (77)

0.27

   Vaginal delivery, n (%)

737

77 (83)

513 (80)

0.48

   Hemoglobin*

737

   

Normal (>11 g/dl), n (%)

364

36 (38.7)

328 (50.9)

 

Mild Anemia (10-11 g/dl), n (%)

210

12 (12.9)

90 (14.0)

0.06

Moderate Anemia (7-10 g/dl), n (%)

140

35 (37.6)

188 (29.2)

 

Severe Anemia (<7 g/dl), n (%)

23

10 (10.8)

38 (5.9)

 

   CD4 cell count (cells/mm3),median (IQR)*

636

366 (217-549)

494 (334-682)

0.01

   Viral load (Log 10) (copies/ml), mean (SD)*

682

4.56 (0.9)

3.73 (1.0)

<0.001

   Maternal HAART, n (%)†

737

14 (15)

48 (8)

0.01

   Maternal AZT, n (%)≠

737

224 (35)

24 (26)

0.09

   Maternal NVP, single-dose, n (%)≠

737

54 (58)

431 (67)

0.09

  1. NOTES:
  2. *Values closest to delivery are reported.
  3. †HAART use during any time of the study.
  4. ‡ P-values based on chi-square, Fisher's exact, Median test or un-paired t-test.
  5. ≠AZT = zidovudine for PMTCT, NVP = nevirapine (intrapartum, single-dose) for PMTCT.